Glaucoma prevalence increases as the population ages. The FDA has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. These eye drops work by reducing the amount of fluid in the eye, thereby lowering intraocular pressure.
Omlonti is a relatively selective prostaglandin EP2 receptor agonist, which increases aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways, and is the only product with this pharmacological action. They are administered as one drop a day in the affected eye. Adverse side effects observed with the use of Omlonti include cystoid macular edema in patients with aphakia or pseudophakia, or other risk factors for macular edema; intraocular inflammation; the potential for increased iris pigmentation and eyelash changes.
As with any medication, it is important to follow the instructions provided by your eyecare provider and to use the medication only as directed. You should also inform your eyecare provider of any other medications you may be taking, as well as any medical conditions you may have, before starting treatment with Omlonti.
https://www.santen.com/content/dam/santen/global/pdf/en/news/20220926-1.pdf
